Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

1. Miles, D.W.
2. Chan, A.
3. Dirix, L.Y.
4. Cortés, J.
5. Pivot, X.
6. Tomczak, P.
7. Delozier, T.
8. Sohn, J.H.
9. Provencher, L.
10. Puglisi, F.
11. Harbeck, N.
12. Steger, G.G.
13. Schneeweiss, A.
14. Wardley, A.M.
15. Chlistalla, A.
16. Romieu, G.